IBB News and Press, iShares Biotechnology ETF From 07/30/22

Per capita U.S. healthcare spending went from $2,968 in 1980 to $12,531 in 2020 (both in 2020 dollars), more than a threefold increase. Amazon announced its plans to acquire primary healthcare company One Medical for $3.9 billion. I believe this deal represents the catalyst for a sign...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

After a difficult first half, healthcare’s defensive capabilities are coming into question, but it outperformed the broader markets on a relative basis. The MSCI World Healthcare Index fell by 10.3% through June 30, 2022, in US dollar terms, compared to a 20.5% decline for the ...

Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. An investment analysis follows in the paragraphs below. Don't live the same year 75 tim...

Biotech stocks, as reflected by the XBI ETF, are down ~40% since Jan 1, 2021, underperforming the broader markets. The drug price control political climate in Washington since January 2021 likely has played a big role in the biotech stock downturn, along with other factors. Attrac...

Massive short interest buildup is like tinder for a bullish fire. Good economic news is the match for the short-covering rally. Healthcare stocks look especially good and should outperform. After several tortuous weeks of abnormal volatility and a directionless trading e...

The Nasdaq Biotechnology ETF is a long-term outperformer but in the last years it lagged it peers. In the last weeks, this industry showed relative strength to the market and a comeback is probable. This assumption is supported by a cheap valuation and bullish price action. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks bottomed in mid-June and have seen some upward momentum since then. The recovery is in line with the broader market. But the industry has yet to get a lift from fundamental improvement. Click to Enlarge ...

Incyte is outperforming the SP 500. Institutions are accumulating shares. My price target on INCY is $100. Incyte Corp. is Moving Higher Incyte Corporation ( INCY ) is a biopharmaceutical company that is outperforming the SP 500 index. There are several bullish i...

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...